Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
August 5th, 2022
DNA methyltransferases are potential cancer drug targets. Here, a protocol is presented to assess small molecules for DNA methyltransferase inhibition. This assay utilizes an endonuclease to couple DNA methylation to fluorescence generation and allows for enzyme activity to be monitored in real time.
A robust plate reader assay like ours is very useful for the initial screening of potential methyltransferase inhibitors. The ability to collect data in real time is a big advantage of the continuous endonuclease-coupled assay. Start by preparing 600 microliters of the assay conditions containing 20 micromolar and 50 micromolar compounds separately in the microcentrifuge tubes on ice.
To do so, add double distilled water and 5X methylation buffer to each tube to achieve a final concentration of 1X methylation buffer. Next, add 3.15 microliters of 20 milligrams per milliliter bovine serum albumen, or BSA, to each sample. Then, add two microliters of 3.15 micromolar hairpin DNA substrate and 1.33 microliters of 4.75 micromolar S-adenosylmethionine, or SAM, to each sample.
Add inhibitor to the appropriate samples to achieve a final concentration of 21 micromolar or 52.5 micromolar and an equivalent amount of dimethyl sulfoxide, or DMSO, to a control sample before mixing the solutions by vortexing at 3, 000 rotations per minute for three seconds. Then, spin the samples for a few seconds in a table table mini centrifuge at 1, 200 times G to ensure the solution is collected at the bottom of the tube. Aliquot 95 microliters of each assay solution into six consecutive wells in a black half area 96 well plate.
Prepare 75 microliters of Gla I or DNMT1 plus Gla I enzyme solution in the microcentrifuge tubes as described before to a final concentration of one-time buffer. Next, add 1.2 microliters of 10 units per microliter Gla I to each solution to achieve a final concentration of 0.16 units per microliter. Add 0.6 microliters of five micromolar RFTS-lacking DNMT1 to the DNMT1 plus Gla I solution for a final concentration of 40 nanomolar.
After gentle mixing, spin the samples for a few seconds in a tabletop mini centrifuge at 1, 200 G to ensure that the solution is collected at the bottom of the tube. Then, aliquot 12 microliters of each enzyme solution into six wells in a conical-bottomed 96 well plate. For the methylation assay of the DNA sample, preheat the plate reader to 37 degrees Celsius.
Then, insert the black plate containing the assay solutions in the plate reader. After shaking the plate at 425 CPM, measure the fluorescence with an excitation wavelength of 485 nanometers and an emission wavelength of 528 nanometers. Then, incubate the plate at 37 degrees Celsius for five minutes.
Remove the assay plate from the plate reader and add five microliters of the enzyme solution to each well, followed by mixing the solution by pipetting up and down. Insert the plate into the plate reader and shake the plate before recording the fluorescence every 53 seconds for 30 minutes. Obtain the average fluorescence of the triplicate Gla I control assays for each condition and subtract the average Gla I containing control reaction trays from the triplicate traces obtained in the presence of RFTS-lacking DNMT1.
Then, determine the average and standard error of the mean for the corrected replicates. Plot the average corrected reaction trace and fit the initial linear portion to a line to determine the initial velocity. Determine the percent activity by dividing the velocity observed in the presence of a compound by the velocity observed in the DMSO containing control reaction and multiplying by 100.
The results of a discontinuous endonuclease-coupled assay showed that fully methylated product DNA is protected from cleavage, confirming that RFTS-lacking DNMT1 is active and able to methylate the hemimethylated substrate DNA. In the fluorescence-based assay, in the absence of Gla I, the addition of DNMT1 or buffer alone did not affect the background fluorescence. Subsequent addition of Gla I to all assays resulted in fluorescence generation only in assays that contained DNMT1.
The concurrent addition of RFTS-lacking DNMT1 and Gla I to three assays resulted in robust fluorescence generation. The addition of Gla I alone produced no fluorescence. To screen for potential inhibitors, the DNA methylation activity of RFTS-lacking DNMT1 was examined in the presence of DMSO, compound one, compound two, or compound three at 20 and 50 micromolar concentrations.
The compounds that reduce fluorescence generation in this coupled assay must be further validated. Ensuring the compounds are not inhibiting the coupling enzyme is an important next step.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for assessing small molecules as potential inhibitors of DNA methyltransferases, which are important targets in cancer therapy. The assay employs an endonuclease to link DNA methylation to fluorescence, enabling real-time monitoring of enzyme activity.
Key Study Components
Area of Science
- Neuroscience
- Biochemistry
- Cancer Research
Background
- DNA methyltransferases play a critical role in gene regulation and cancer.
- Inhibiting these enzymes could provide therapeutic benefits in cancer treatment.
- Real-time assays enhance the screening process for potential inhibitors.
- Fluorescence-based methods allow for sensitive detection of enzyme activity.
Purpose of Study
- To develop a robust assay for screening DNA methyltransferase inhibitors.
- To utilize real-time data collection for improved assay performance.
- To facilitate the identification of small molecules that can inhibit DNA methyltransferase activity.
Methods Used
- Preparation of assay conditions with specific concentrations of compounds.
- Use of bovine serum albumen (BSA) in the assay setup.
- Incorporation of hairpin DNA substrate and S-adenosylmethionine (SAM).
- Monitoring enzyme activity through fluorescence generation.
Main Results
- The assay allows for continuous monitoring of DNA methyltransferase activity.
- Real-time data collection provides a significant advantage over traditional methods.
- Initial screening of compounds shows promise in identifying potential inhibitors.
- The method is adaptable for various small molecule libraries.
Conclusions
- The developed assay is effective for screening DNA methyltransferase inhibitors.
- Real-time monitoring enhances the reliability of the results.
- This approach could accelerate the discovery of new cancer therapeutics.
Frequently Asked Questions
Executive Industry Relevance
This continuous fluorescence-based endonuclease-coupled assay enables real-time monitoring of DNA methyltransferase activity, supporting early-stage screening of small molecule inhibitors. By providing quantitative initial velocity measurements in a microtiter plate format, the method reduces reagent consumption and increases throughput for target validation campaigns. The assay’s ability to detect concentration-dependent inhibition aids in prioritizing compounds with mechanistic relevance to epigenetic dysregulation in cancer.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of DNMT1 inhibition kinetics to validate epigenetic targets in oncology pipelines.
- Operational Value: Supports rapid assessment of small molecule effects on enzyme activity using fluorescence readouts in a plate-based format.
Screening & Assay Development
- Scientific Value: Generates real-time, continuous data to distinguish true inhibitors from assay artifacts in primary screens.
- Operational Value: Compatible with standard plate readers and microtiter plates, enabling scalable screening of compound libraries.
Translational & Preclinical Research
- Scientific Value: Links biochemical inhibition of DNMT1 to downstream epigenetic effects, supporting mechanistic de-risking of lead candidates.
- Operational Value: Provides a reproducible platform for hit-to-lead progression where target engagement is a key decision criterion.
Pipeline & Workflow Integration
The assay fits within the early discovery workflow, positioning after target confirmation and before lead optimization, where biochemical validation of target modulation is essential.
- Discovery Biology: Facilitates hypothesis testing of DNMT1 inhibition as a mechanism for altering DNA methylation patterns in disease models.
- Screening: Enables primary screening of compound libraries with real-time kinetic readouts to identify active molecules.
- Analytics: Delivers initial velocity and percent activity outputs that allow quantitative comparison of inhibitor potency across conditions.
- Translational Research: Supports continuity from enzymatic inhibition to cellular epigenetic outcomes when paired with downstream validation assays.
- Enterprise Reuse: Can be adapted for screening other DNMT isoforms or methyltransferase targets using the same endonuclease-coupled fluorescence principle.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target modulation by providing direct, real-time measurement of enzyme activity changes.
- Operational Value: Reduces reagent use and assay time through miniaturized, continuous monitoring in a 96-well format.
- Strategic Value: Improves go/no-go decisions by distinguishing specific DNMT1 inhibitors from non-specific fluorescence interferents early in screening.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds demonstrating concentration-dependent, mechanism-consistent inhibition.
Implementation Considerations
- Requires expertise in enzymology and fluorescence-based assay design to interpret kinetic traces and control for background signals.
- Dependent on access to a plate reader capable of temperature control and timed fluorescence excitation at 485 nm and emission at 528 nm.
- Necessitates standardization of reagent preparation, including hemimethylated DNA substrate, SAM, BSA, and Gla I endonuclease, to ensure assay reproducibility.
- Requires validation that test compounds do not inhibit the coupling enzyme Gla I or interfere with fluorescence independently.
- Limited to methyltransferase activity assessment and does not directly report on cellular permeability, metabolic stability, or off-target effects.
Biopharma FAQs
Chapters in this video
0:05
Introduction
0:24
Prepare Assay Solutions for the Screen
1:48
Prepare Enzyme Solutions for the Screen
2:52
Run the Methylation Assay and Analyze the Data
4:29
Results: Determination of Initial Velocities of DNA Methylation in the Presence and Absence of Potential Inhibitors
5:40
Conclusion
